METLIFE PRICES REMARKETING OF SERIES E SENIOR COMPONENT DEBENTURES
New York, September 30, 2014
MetLife, Inc. (NYSE: MET) announced today the pricing of its remarketing of $499,924,000 aggregate principal amount of its 1.903% Series E Senior Component Debentures, Tranche 1 and $499,924,000 aggregate principal amount of its 4.721% Series E Senior Component Debentures, Tranche 2. Both tranches originally comprised part of the $1 billion aggregate principal amount of MetLife’s Series E Senior Debentures due 2045 and formed part of its 40 million common equity units, which were issued in November 2010 in connection with MetLife’s acquisition of American Life Insurance Company and Delaware American Life Insurance Company.
Following the settlement of the remarketing, the stated maturity of the Tranche 1 and Tranche 2 Debentures will, effective October 8, 2014, be adjusted to December 15, 2017 and December 15, 2044, respectively. Proceeds of the remarketing, net of the remarketing agents’ fees, will be paid to the holders of the common equity units who participated in the remarketing. MetLife, Inc. will ultimately receive $1 billion in the aggregate from the proceeds of the remarketing and from holders that elected not to participate in the remarketing in return for delivering newly-issued shares of MetLife common stock to all holders of common equity units upon settlement of the related stock purchase contracts.
Deutsche Bank Securities, Citigroup, Credit Suisse, Goldman, Sachs & Co., HSBC, UBS Investment Bank and Wells Fargo Securities acted as lead remarketing agents.
This news release is neither an offer to sell, nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.
MetLife has filed a registration statement, including a prospectus supplement and the accompanying prospectus, with the Securities and Exchange Commission for the offering to which this news release relates. These documents can be accessed at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, these documents can be requested from Deutsche Bank Securities Inc., Attn.: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, telephone: (800) 503-4611, email: prospectus.CPDG@db.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) 831-9146, email: email@example.com; Credit Suisse Securities (USA) LLC, Attn.: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, telephone: (800) 221-1037; Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526, facsimile: (212) 902-9316, email: firstname.lastname@example.org; HSBC Securities (USA) Inc., Attn.: Syndicate Desk, 452 Fifth Avenue, New York, NY 10018, telephone: (866) 811-8049; UBS Securities LLC, at 299 Park Avenue, New York, NY 10171, Attn: Prospectus Specialist, telephone: (877) 827-6444, ext. 561 3884; or Wells Fargo Securities, LLC, 1525 West W.T. Harris Blvd., NC0675, Charlotte, North Carolina 28262, Attn.: Capital Markets Client Support, telephone: (800) 326-5897, email: email@example.com.
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the largest life insurance companies in the world. Founded in 1868, MetLife is a global provider of life insurance, annuities, employee benefits and asset management. Serving approximately 100 million customers, MetLife has operations in nearly 50 countries and holds leading market positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.
This news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining the actual future results of MetLife, Inc., its subsidiaries and affiliates. These statements are based on current expectations and the current economic environment. They involve a number of risks and uncertainties that are difficult to predict. These statements are not guarantees of future performance. Actual results could differ materially from those expressed or implied in the forward-looking statements. Risks, uncertainties, and other factors that might cause such differences include the risks, uncertainties and other factors identified in MetLife, Inc.’s most recent Annual Report on Form 10-K (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (the “SEC”), Quarterly Reports on Form 10-Q filed by MetLife, Inc. with the SEC after the date of the Annual Report under the captions “Note Regarding Forward-Looking Statements” and “Risk Factors,” and other filings MetLife, Inc. makes with the SEC. MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in reports to the SEC.